Relapse after chemotherapy is a significant challenge in the treatment of acute myeloid leukemia.[18] It has been shown that VLA‐4 was highly expressed in acute myeloid leukemia cells and was closely related to chemoresistance.[17a] Therefore, a VLA‐4‐targeting peptide (V9) was genetically displayed on the surface of HFn‐Se to generate V9‐HFn‐Se that could target tumor cells through binding to TfR1 and VLA‐4 (Figure 2A). Here, TFRC is linked to neoplasm.